NCT01405885 - A Study of DNA Vaccine With Electroporation for the Prevention of Disease Caused by H1 and H5 Influenza Virus | Biotech Hunter

Enrollment

116

Participants

Timeline

Start Date

May 31, 2011

Primary Completion Date

August 31, 2013

Study Completion Date

August 31, 2013

Conditions

Healthy

Interventions

BIOLOGICAL

INO-3605

0.9mg of INO-3605 vaccine delivered ID followed by electroporation on Day 0, Week 8 and 24.

BIOLOGICAL

INO-3609

0.9mg of INO-3609 vaccine delivered ID followed by electroporation on Day 0, Week 8 and 24.

BIOLOGICAL

INO-3401

0.9mg of 3401 vaccine delivered ID followed by electroporation on Day 0, Week 8 and 24.

BIOLOGICAL

INO-3609

0.3mg of INO-3609 vaccine delivered ID followed by electroporation on Day 0, Week 8 and 24.

BIOLOGICAL

INO-3605 AND INO-3609

0.45mg each of INO-3605 AND INO-3609 vaccine delivered ID followed by electroporation on Day 0, Week 8 and 24.

BIOLOGICAL

INO-3510

0.3mg each of INO-3605, INO-3609 AND INO-3401 vaccine delivered ID followed by electroporation on Day 0, Week 8 and 24.

BIOLOGICAL

INO-3609

0.9mg of INO-3609 vaccine delivered ID followed by electroporation on Day 0, Week 16 and 24.

BIOLOGICAL

INO-3609

0.9mg of INO-3609 vaccine delivered ID followed by electroporation on Day 0 and Week 8

BIOLOGICAL

Seasonal Influenza vaccine

0.5ml of vaccine delivered IM

BIOLOGICAL

INO-3609

1.8mg of INO-3609 vaccine delivered ID followed by electroporation on Day 0, Week 8 and 24.

Trial Locations (3)

21201

SNBL, Baltimore

33143

Miami Research Associates, Miami

66212

Vince and Associates, Overland Park